| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:LCOR_MAP2K6 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: LCOR_MAP2K6 | KinaseFusionDB ID: KFG3136 | FusionGDB2.0 ID: KFG3136 | Hgene | Tgene | Gene symbol | LCOR | MAP2K6 | Gene ID | 84458 | 5608 | |
| Gene name | ligand dependent nuclear receptor corepressor | mitogen-activated protein kinase kinase 6 | ||||||||||
| Synonyms | C10orf12|MLR2 | MAPKK6|MEK6|MKK6|PRKMK6|SAPKK-3|SAPKK3 | ||||||||||
| Cytomap | 10q24.1 | 17q24.3 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | ligand-dependent corepressormblk1-related protein 2 | dual specificity mitogen-activated protein kinase kinase 6MAPK/ERK kinase 6MAPKK 6MEK 6SAPK kinase 3protein kinase, mitogen-activated, kinase 6 (MAP kinase kinase 6)stress-activated protein kinase kinase 3 | ||||||||||
| Modification date | 20240305 | 20240403 | ||||||||||
| UniProtAcc | Q96JN0 | P52564 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000356016, ENST00000371097, ENST00000371103, ENST00000540664, ENST00000498444, | ENST00000589647, ENST00000590474, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: LCOR [Title/Abstract] AND MAP2K6 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | LCOR(98667504)-MAP2K6(67521042), # samples:3 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | LCOR | GO:0000122 | negative regulation of transcription by RNA polymerase II | 12535528 |
| Hgene | LCOR | GO:0071392 | cellular response to estradiol stimulus | 12535528 |
| Tgene | MAP2K6 | GO:0000165 | MAPK cascade | 8663074 |
| Tgene | MAP2K6 | GO:0031098 | stress-activated protein kinase signaling cascade | 35857590 |
| Tgene | MAP2K6 | GO:0038066 | p38MAPK cascade | 11460167 |
| Tgene | MAP2K6 | GO:0051403 | stress-activated MAPK cascade | 8663524|9218798 |
| Kinase Fusion gene breakpoints across LCOR (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across MAP2K6 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-DK-AA76-01A | LCOR | chr10 | 98667504 | MAP2K6 | chr17 | 67521042 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:98667504/:67521042) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| LCOR | MAP2K6 |
| FUNCTION: May act as transcription activator that binds DNA elements with the sequence 5'-CCCTATCGATCGATCTCTACCT-3' (By similarity). Repressor of ligand-dependent transcription activation by target nuclear receptors. Repressor of ligand-dependent transcription activation by ESR1, ESR2, NR3C1, PGR, RARA, RARB, RARG, RXRA and VDR. {ECO:0000250, ECO:0000269|PubMed:12535528}. | FUNCTION: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinases p38 MAPK11, MAPK12, MAPK13 and MAPK14 and plays an important role in the regulation of cellular responses to cytokines and all kinds of stresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are both essential for the activation of MAPK11 and MAPK13 induced by environmental stress, whereas MAP2K6/MKK6 is the major MAPK11 activator in response to TNF. MAP2K6/MKK6 also phosphorylates and activates PAK6. The p38 MAP kinase signal transduction pathway leads to direct activation of transcription factors. Nuclear targets of p38 MAP kinase include the transcription factors ATF2 and ELK1. Within the p38 MAPK signal transduction pathway, MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14 activation, and is therefore required for STAT4 activation and STAT4-regulated gene expression in response to IL-12 stimulation. The pathway is also crucial for IL-6-induced SOCS3 expression and down-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclast differentiation through NF-kappa-B transactivation by TNFSF11, and in endochondral ossification and since SOX9 is another likely downstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediates apoptotic cell death in thymocytes. Acts also as a regulator for melanocytes dendricity, through the modulation of Rho family GTPases. {ECO:0000269|PubMed:10961885, ECO:0000269|PubMed:11727828, ECO:0000269|PubMed:15550393, ECO:0000269|PubMed:20869211, ECO:0000269|PubMed:8622669, ECO:0000269|PubMed:8626699, ECO:0000269|PubMed:8663074, ECO:0000269|PubMed:9218798}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of LCOR_MAP2K6 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| MAP2K6 | P52564 | human | MAPK12 | P53778 | Y185 | ADsEMtGyVVTRWYR | Pkinase |
| MAP2K6 | P52564 | human | HSF4 | Q9ULV5 | T471 | LGLPGALtIYSTPES | |
| MAP2K6 | P52564 | human | MAPK12 | P53778 | T183 | RQADsEMtGyVVTRW | Pkinase |
| MAP2K6 | P52564 | human | PAK6 | Q9NQU5 | Y566 | KsLVGtPyWMAPEVI | Pkinase |
| MAP2K6 | P52564 | human | MAPK13 | O15264 | T180 | RHADAEMtGyVVtRW | Pkinase |
| MAP2K6 | P52564 | human | MAP2K6 | P52564 | S207 | IsGyLVDsVAKtIDA | Pkinase |
| MAP2K6 | P52564 | human | MAP2K6 | P52564 | Y219 | IDAGCKPyMAPERIN | Pkinase |
| MAP2K6 | P52564 | human | MAPK14 | Q16539 | T180 | RHtDDEMtGyVAtRW | Pkinase |
| MAP2K6 | P52564 | human | MAPK13 | O15264 | Y182 | ADAEMtGyVVtRWYR | Pkinase |
| MAP2K6 | P52564 | human | MAPK14 | Q16539 | Y182 | tDDEMtGyVAtRWYR | Pkinase |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| MAP2K6 | ID | Description | 0.00e+00 |
| MAP2K6 | GO:0042770 | signal transduction in response to DNA damage | 4.08e-03 |
| MAP2K6 | GO:0051403 | stress-activated MAPK cascade | 4.08e-03 |
| MAP2K6 | GO:0031098 | stress-activated protein kinase signaling cascade | 4.08e-03 |
| MAP2K6 | GO:0018105 | peptidyl-serine phosphorylation | 5.28e-03 |
| MAP2K6 | GO:0018209 | peptidyl-serine modification | 5.28e-03 |
| MAP2K6 | GO:0038066 | p38MAPK cascade | 7.07e-03 |
| MAP2K6 | GO:0051149 | positive regulation of muscle cell differentiation | 1.29e-02 |
| MAP2K6 | GO:0034644 | cellular response to UV | 1.32e-02 |
| MAP2K6 | GO:0045445 | myoblast differentiation | 1.58e-02 |
| MAP2K6 | GO:0090398 | cellular senescence | 1.58e-02 |
| MAP2K6 | GO:0071482 | cellular response to light stimulus | 1.80e-02 |
| MAP2K6 | GO:0071322 | cellular response to carbohydrate stimulus | 2.32e-02 |
| MAP2K6 | GO:0009411 | response to UV | 2.32e-02 |
| MAP2K6 | GO:0051147 | regulation of muscle cell differentiation | 2.44e-02 |
| MAP2K6 | GO:0071478 | cellular response to radiation | 2.84e-02 |
| MAP2K6 | GO:0060348 | bone development | 3.74e-02 |
| MAP2K6 | GO:0009743 | response to carbohydrate | 4.02e-02 |
| MAP2K6 | GO:0001649 | osteoblast differentiation | 4.72e-02 |
| MAP2K6 | GO:0070391 | response to lipoteichoic acid | 4.75e-02 |
| MAP2K6 | GO:0071223 | cellular response to lipoteichoic acid | 4.75e-02 |
| MAP2K6 | GO:0071493 | cellular response to UV-B | 4.75e-02 |
| MAP2K6 | GO:0009416 | response to light stimulus | 4.75e-02 |
| MAP2K6 | GO:0032306 | regulation of prostaglandin secretion | 4.75e-02 |
| MAP2K6 | GO:0032308 | positive regulation of prostaglandin secretion | 4.75e-02 |
| MAP2K6 | GO:0035331 | negative regulation of hippo signaling | 4.75e-02 |
| MAP2K6 | GO:0071214 | cellular response to abiotic stimulus | 4.75e-02 |
| MAP2K6 | GO:0104004 | cellular response to environmental stimulus | 4.75e-02 |
| MAP2K6 | GO:0007517 | muscle organ development | 4.75e-02 |
| MAP2K6 | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 4.75e-02 |
| MAP2K6 | GO:0090336 | positive regulation of brown fat cell differentiation | 4.75e-02 |
| MAP2K6 | GO:1901741 | positive regulation of myoblast fusion | 4.75e-02 |
| MAP2K6 | GO:0010831 | positive regulation of myotube differentiation | 4.75e-02 |
| MAP2K6 | GO:0032310 | prostaglandin secretion | 4.75e-02 |
| MAP2K6 | GO:0071243 | cellular response to arsenic-containing substance | 4.75e-02 |
| MAP2K6 | GO:0001502 | cartilage condensation | 4.75e-02 |
| MAP2K6 | GO:0032305 | positive regulation of icosanoid secretion | 4.75e-02 |
| MAP2K6 | GO:0032303 | regulation of icosanoid secretion | 4.75e-02 |
| MAP2K6 | GO:0051767 | nitric-oxide synthase biosynthetic process | 4.75e-02 |
| MAP2K6 | GO:0051769 | regulation of nitric-oxide synthase biosynthetic process | 4.75e-02 |
| MAP2K6 | GO:0045786 | negative regulation of cell cycle | 4.75e-02 |
| MAP2K6 | GO:0010224 | response to UV-B | 4.75e-02 |
| MAP2K6 | GO:0032495 | response to muramyl dipeptide | 4.75e-02 |
| MAP2K6 | GO:1901739 | regulation of myoblast fusion | 4.75e-02 |
| MAP2K6 | GO:0042692 | muscle cell differentiation | 4.75e-02 |
| MAP2K6 | GO:0050727 | regulation of inflammatory response | 4.75e-02 |
| MAP2K6 | GO:0009314 | response to radiation | 4.75e-02 |
| MAP2K6 | GO:0098743 | cell aggregation | 4.75e-02 |
| MAP2K6 | GO:2000193 | positive regulation of fatty acid transport | 4.75e-02 |
| MAP2K6 | GO:0060143 | positive regulation of syncytium formation by plasma membrane fusion | 4.75e-02 |
Top |
Related Drugs to LCOR_MAP2K6 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning LCOR-MAP2K6 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to LCOR_MAP2K6 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |